Inihibition of Glycolysis by Using a Micro/Nano-Lipid Bromopyruvic Chitosan Carrier as a Promising Tool to Improve Treatment of Hepatocellular Carcinoma

Glucose consumption in many types of cancer cells, in particular hepatocellular carcinoma (HCC), was followed completely by over-expression of type II hexokinase (HKII). This evidence has been used in modern pharmacotherapy to discover therapeutic target against glycolysis in cancer cells. Bromopyru...

全面介紹

書目詳細資料

發表在:	Nanomaterials
Main Authors:	Nemany A. Hanafy, Luciana Dini, Cinzia Citti, Giuseppe Cannazza, Stefano Leporatti
格式:	Article
語言:	英语
出版:	MDPI AG 2018-01-01
主題:	nanocarrier glycolysis hepatocellular carcinoma (HCC) bromopyruvate
在線閱讀:	http://www.mdpi.com/2079-4991/8/1/34